Skip to main content

Table 2 Clinico-pathological characteristics and β-catenin and cyclin-D1 protein expression in 50 patients with esophageal cancer

From: Aberrant nuclear localization of β-catenin without genetic alterations in β-catenin or Axin genes in esophageal cancer

 

age/sex

follow-up(M)

out comea)

T

N

stage

lyb)

vc)

diffd)

β-catenine)

cyclin D1

1

67M

31

D.O

1

0

I

0

0

M

M

+

2

46M

24

A

1

0

I

0

0

M

C

-

3

68M

26

A

1

1

I

1

1

W

N+C+M

+

4

56M

11

A

1

0

I

0

0

M

M

-

5

68M

18

A

1

0

I

0

0

M

M

+

6

66M

36

D.E

3

0

II

2

1

M

C+M

-

7

73F

38

A

2

1

II

1

0

W

M

-

8

69M

2

D.O

1

2

II

0

0

W

M

-

9

60M

32

A

1

2

II

0

0

W

M

+

10

58M

16

D.E

1

1

II

1

1

P

N+C

+

11

79F

30

D.E

3

0

III

1

1

W

N+C

+

12

69M

8

D.E

3

2

III

1

0

M

C+M

-

13

58M

12

D.E

3

1

III

1

1

P

M

+

14

66M

11

D.E

3

1

III

1

1

M

C

-

15

66F

39

D.E

3

2

III

1

1

P

C

-

16

54F

16

D.E

3

3

III

1

0

W

C+M

-

17

52F

15

D.E

3

2

III

2

1

W

M

+

18

68M

12

D.E

3

1

III

U

U

n.a.

M

+

19

68M

26

D.E

3

2

III

1

2

W

M

-

20

68M

12

D.E

3

1

III

2

1

M

M

+

21

57F

14

D.E

3

2

III

2

2

W

M

+

22

61F

6

D.E

3

2

III

1

0

W

M

-

23

63M

28

D.O

3

3

III

3

1

M

C

+

24

47F

22

A

3

2

III

1

0

W

M

+

25

50M

29

A

3

2

III

1

1

P

C+M

+

26

68M

9

D.E

3

2

III

1

1

M

M

-

27

70F

4

D.E

3

2

III

1

0

W

M

-

28

56M

18

A

3

2

III

1

0

W

M

-

29

68M

9

D.E

4

0

III

U

U

U

M

+

30

68M

15

D.E

3

3

III

2

2

P

M

-

31

75M

6

D.E

4

3

IV

U

U

W

M

-

32

51F

9

D.E

4

2

IV

2

2

M

M

+

33

67M

2

D.E

4

2

IV

U

U

n.a.

M

-

34

55M

6

D.E

4

4

IV

U

U

M

M

-

35

51M

2

D.E

2

4

IV

0

0

M

M

+

36

69M

8

D.E

4

3

IV

U

U

W

C

+

37

62M

7

D.E

4

2

IV

1

1

W

M

-

38

45M

8

D.E

4

3

IV

1

0

W

M

+

39

46M

3

D.E

4

4

IV

2

1

M

M

+

40

52M

14

D.E

3

4

IV

1

1

M

C

+

41

72M

5

D.E

3

4

IV

2

2

M

M

-

42

53M

13

D.E

4

2

IV

1

0

M

M

+

43

76M

11

D.E

4

3

IV

1

1

M

M

+

44

64M

6

D.O

4

2

IV

1

1

M

M

-

45

51M

6

D.E

4

4

IV

U

U

W

M

-

46

58M

22

A

4

3

IV

U

U

M

C+M

-

47

69M

2

D.E

3

4

IV

2

1

W

C

+

48

57M

13

D.E

4

2

IV

2

2

M

M

-

49

72M

14

D.E

4

1

IV

1

1

W

C

-

50

60M

18

A

4

4

IV

2

1

M

N+C

+

  1. All the samples except cases 18 (unknown) and 33 (adenosquamous carcinoma) were squamous cell carcinomas.
  2. a) D.O; dead with other disease, A; alive D.E; dead with esophageal cancer
  3. b) ly; grade of lymphatic invasion, U; unknown c) v; grade of venous invasion, U; unknown
  4. d) differentiation, W; well differentiated, M; moderately differentiated, P; poorly differentiated, U; unknown, n.a.; not applicable
  5. e) localization by immunostaining, M; membrane, C; cytoplasmic N; nuclear staining
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us